Efficacy and Safety of Empagliflozin in Elderly Japanese Adults With Type 2 Diabetes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Diabetes, Obesity & Metabolism
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and safety of the sodium-glucose co-transporter-2 inhibitor empagliflozin in elderly Japanese adults (≥65 years) with type 2 diabetes: A randomized, double-blind, placebo-controlled, 52-week clinical trial (EMPA-ELDERLY)
Diabetes Obes Metab 2023 Aug 25;[EPub Ahead of Print], D Yabe, K Shiki, G Homma, T Meinicke, Y Ogura, Y SeinoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.